top of page

Cytora participates in the BIO International Convention in San Diego

22-25 June 2026

Recently San Diego took the focus with the BIO International Convention 2026, bringing together nearly 20,000 leaders from across the global biotechnology and pharmaceutical ecosystem, anchored by BIO’s One‑on‑One Partnering platform and a 900+ exhibitor floor and 100+ sessions highlighted critical frontiers in medicine and biopharma.

​

Cytora’s CEO, Dr Yona Geffen actively leveraged the One‑on‑One Partnering system, completing more than 25 meetings to advance strategic collaborations and investor discussions.

​

It was inspiring to connect with a diverse group reflecting the full value chain—from discovery through market access including biopharma and emerging biotech executives, investors and venture funds, CDMOs, CROs, regulators, policy experts, and patient organizations.

​

The future of healthcare is collaborative, and we are thrilled to be driving it forward.

Cytora bottom logo

MENU

Cytora’s patented platform technology is based on the discovery of a novel and unique stem cell population in the human oral mucosa (hOMSC), the origin of which is the embryonic nervous system. hOMSC are endowed with properties of neural crest, neural and mesenchymal stem cells. Cytora’s products are allogeneic, off-the-shelf, easily scalable, with a very competitive cost of goods (COG). The products were found to be safe and effective in early phase clinical trials in two indications: Diabetic Foot Ulcers (DFU) and Multiple System Atrophy (MSA).

Our products have high potential for treating complicated multifactorial diseases such as chronic and neurodegenerative diseases, incurable wounds and autoimmune diseases.

ABOUT US

TECHNOLOGY

PIPELINE

TEAM

PUBLICATIONS

NEWS AND EVENTS

CONTACT US

CONTACT US

info@cytorastem.com

© 2022 Cytora. All rights reserved.

bottom of page